- 
             Something wrong with this record ?
 
Acquired Resistance to Decitabine Associated with the Deoxycytidine Kinase A180P Mutation: Implications for the Order of Hypomethylating Agents in Myeloid Malignancies Treatment
K. Simonicova, L. Janotka, H. Kavcova, I. Borovska, Z. Sulova, A. Breier, L. Messingerova
Language English Country Switzerland
Document type Journal Article
        Grant support
          
              APVV-19-0093 
          
      Slovak Agency for Research and Development   
      
          
              APVV-19-0094 
          
      Slovak Agency for Research and Development   
      
          
              VEGA 2/0016/22 
          
      Grant Agency of the Ministry of Education of the Slovak Republic and the Slovak Academy of Sciences   
      
          
              CA21154 project 
          
      MVTS   
      
      
 NLK 
   
      Free Medical Journals
   
    from 2000
   
      Freely Accessible Science Journals
   
    from 2000
   
      PubMed Central
   
    from 2007
   
      Europe PubMed Central
   
    from 2007
   
      ProQuest Central
   
    from 2000-03-01
   
      Open Access Digital Library
   
    from 2000-01-01
   
      Open Access Digital Library
   
    from 2007-01-01
   
      Health & Medicine (ProQuest)
   
    from 2000-03-01
   
      ROAD: Directory of Open Access Scholarly Resources
   
    from 2000
    
    PubMed
          
           40507894
           
          
          
    DOI
          
           10.3390/ijms26115083
           
          
          
  
    Knihovny.cz E-resources
    
  
              
      
- MeSH
- Leukemia, Myeloid, Acute * genetics drug therapy MeSH
- Azacitidine * pharmacology analogs & derivatives MeSH
- Drug Resistance, Neoplasm * genetics drug effects MeSH
- Cytarabine pharmacology MeSH
- Decitabine * pharmacology MeSH
- Deoxycytidine analogs & derivatives pharmacology MeSH
- Deoxycytidine Kinase * genetics metabolism MeSH
- HEK293 Cells MeSH
- Humans MeSH
- Mutation MeSH
- Cell Line, Tumor MeSH
- Antimetabolites, Antineoplastic * pharmacology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
The backbone of therapy for elderly patients with myelodysplastic syndromes and acute myeloid leukemia consists of hypomethylating agents 5-aza-2'-deoxycytidine (DAC) and 5-azacytidine (AZA). However, resistance frequently emerges during treatment. To investigate the mechanisms of resistance, we generated DAC-resistant variants of the acute myeloid leukemia cell lines, MOLM-13 and SKM-1, through their prolonged cultivation in increasing concentrations of DAC. The resistant cell variants, MOLM-13/DAC and SKM-1/DAC, exhibited cross-resistance to cytarabine and gemcitabine, but remained sensitive to AZA. Existing studies have suggested that the loss of deoxycytidine kinase (DCK) may play an important role in DAC resistance. DCK is critical for DAC activation, but the precise mechanisms of its downregulation remain incompletely understood. We identified a novel point mutation (A180P) in DCK, which results in acquired DAC resistance. Although the DCK mRNA was actively transcribed, the mutant protein was not detected in DAC-resistant cells. The transfection of HEK293 cells with the mutant DCK, combined with proteasomal inhibition, revealed rapid proteasomal degradation, establishing a mechanistic link between the A180P mutation and DCK loss, not previously described. This highlights the importance of also evaluating DCK at the protein and/or enzymatic activity levels in patients. The loss of functional DCK impairs the phosphorylation of deoxynucleosides, conferring resistance to DAC, gemcitabine, and cytarabine, but AZA, phosphorylated by uridine-cytidine kinase, remains effective and may represent a therapeutic alternative for patients with acquired DAC resistance.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015662
- 003
- CZ-PrNML
- 005
- 20250731091144.0
- 007
- ta
- 008
- 250708s2025 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ijms26115083 $2 doi
- 035 __
- $a (PubMed)40507894
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Simonicova, Kristina $u Institute of Molecular Physiology and Genetics, Centre of Biosciences, Slovak Academy of Sciences, Dúbravská cesta 9, 840 05 Bratislava, Slovakia $1 https://orcid.org/0009000443181080
- 245 10
- $a Acquired Resistance to Decitabine Associated with the Deoxycytidine Kinase A180P Mutation: Implications for the Order of Hypomethylating Agents in Myeloid Malignancies Treatment / $c K. Simonicova, L. Janotka, H. Kavcova, I. Borovska, Z. Sulova, A. Breier, L. Messingerova
- 520 9_
- $a The backbone of therapy for elderly patients with myelodysplastic syndromes and acute myeloid leukemia consists of hypomethylating agents 5-aza-2'-deoxycytidine (DAC) and 5-azacytidine (AZA). However, resistance frequently emerges during treatment. To investigate the mechanisms of resistance, we generated DAC-resistant variants of the acute myeloid leukemia cell lines, MOLM-13 and SKM-1, through their prolonged cultivation in increasing concentrations of DAC. The resistant cell variants, MOLM-13/DAC and SKM-1/DAC, exhibited cross-resistance to cytarabine and gemcitabine, but remained sensitive to AZA. Existing studies have suggested that the loss of deoxycytidine kinase (DCK) may play an important role in DAC resistance. DCK is critical for DAC activation, but the precise mechanisms of its downregulation remain incompletely understood. We identified a novel point mutation (A180P) in DCK, which results in acquired DAC resistance. Although the DCK mRNA was actively transcribed, the mutant protein was not detected in DAC-resistant cells. The transfection of HEK293 cells with the mutant DCK, combined with proteasomal inhibition, revealed rapid proteasomal degradation, establishing a mechanistic link between the A180P mutation and DCK loss, not previously described. This highlights the importance of also evaluating DCK at the protein and/or enzymatic activity levels in patients. The loss of functional DCK impairs the phosphorylation of deoxynucleosides, conferring resistance to DAC, gemcitabine, and cytarabine, but AZA, phosphorylated by uridine-cytidine kinase, remains effective and may represent a therapeutic alternative for patients with acquired DAC resistance.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a decitabin $x farmakologie $7 D000077209
- 650 12
- $a deoxycytidinkinasa $x genetika $x metabolismus $7 D003842
- 650 12
- $a chemorezistence $x genetika $x účinky léků $7 D019008
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 12
- $a protinádorové antimetabolity $x farmakologie $7 D000964
- 650 12
- $a azacytidin $x farmakologie $x analogy a deriváty $7 D001374
- 650 _2
- $a HEK293 buňky $7 D057809
- 650 12
- $a akutní myeloidní leukemie $x genetika $x farmakoterapie $7 D015470
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a cytarabin $x farmakologie $7 D003561
- 650 _2
- $a deoxycytidin $x analogy a deriváty $x farmakologie $7 D003841
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Janotka, Lubos $u Institute of Molecular Physiology and Genetics, Centre of Biosciences, Slovak Academy of Sciences, Dúbravská cesta 9, 840 05 Bratislava, Slovakia $u Department of Biology, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hnevotinska 3, 77515 Olomouc, Czech Republic
- 700 1_
- $a Kavcova, Helena $u Institute of Molecular Physiology and Genetics, Centre of Biosciences, Slovak Academy of Sciences, Dúbravská cesta 9, 840 05 Bratislava, Slovakia
- 700 1_
- $a Borovska, Ivana $u Institute of Molecular Physiology and Genetics, Centre of Biosciences, Slovak Academy of Sciences, Dúbravská cesta 9, 840 05 Bratislava, Slovakia $1 https://orcid.org/000000028090387X
- 700 1_
- $a Sulova, Zdena $u Institute of Molecular Physiology and Genetics, Centre of Biosciences, Slovak Academy of Sciences, Dúbravská cesta 9, 840 05 Bratislava, Slovakia $1 https://orcid.org/0000000176034491
- 700 1_
- $a Breier, Albert $u Institute of Molecular Physiology and Genetics, Centre of Biosciences, Slovak Academy of Sciences, Dúbravská cesta 9, 840 05 Bratislava, Slovakia $u Institute of Biochemistry and Microbiology, Faculty of Chemical and Food Technology, Slovak University of Technology in Bratislava, Radlinského 9, 812 37 Bratislava, Slovakia $1 https://orcid.org/000000032174786X $7 xx0194103
- 700 1_
- $a Messingerova, Lucia $u Institute of Molecular Physiology and Genetics, Centre of Biosciences, Slovak Academy of Sciences, Dúbravská cesta 9, 840 05 Bratislava, Slovakia $u Institute of Biochemistry and Microbiology, Faculty of Chemical and Food Technology, Slovak University of Technology in Bratislava, Radlinského 9, 812 37 Bratislava, Slovakia $1 https://orcid.org/0000000279665560
- 773 0_
- $w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 26, č. 11 (2025)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40507894 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091138 $b ABA008
- 999 __
- $a ok $b bmc $g 2366487 $s 1252787
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 26 $c 11 $e 20250525 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- GRA __
- $a APVV-19-0093 $p Slovak Agency for Research and Development
- GRA __
- $a APVV-19-0094 $p Slovak Agency for Research and Development
- GRA __
- $a VEGA 2/0016/22 $p Grant Agency of the Ministry of Education of the Slovak Republic and the Slovak Academy of Sciences
- GRA __
- $a CA21154 project $p MVTS
- LZP __
- $a Pubmed-20250708
